Nangibotide

Cash and cash equivalents of €95.6 million as of September 30, 2026; expected to fund the Company beyond 2028, with continued revenue growth and disciplined spending thereafter expected to drive GENFIT toward profitability €36.3 million in revenue for the first nine months of 2026 from royalties on Ipsen’s sales of Iqirvo® (elafibranor), an increase of 188% year-over-year PBC: Ipsen reported €283m in Iqirvo® net sales in the first nine months of 2026, up 170.8% year-over-year, supporting GENFIT’s expectation that a new commercial sales milestone could be reached based on full-year 2026 net sales MASH: NIS™ Technology gaining momentum following Medicare reimbursement for Labcorp’s NASHnext® in August Clinical pipeline: Three Phase 2 clinical trials advancing in ACLF and CCA, with data readouts targeted for 2027 Lille (France); Cambridge, (Massachusetts, United States); November 5, 2026 - GENFIT (Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces its third quarter 2026 financial results 1 and provides a corporate update. Cash and Revenue Cash position As of September 30, 2026, the Company’s cash and cash equivalents amounted to €95.6 million compared with €113.8 million as of June 30, 2026, and €101.1 million as of December 31, 2025. In 2026, cash consumption was primarily driven by research and development activities across our Acute-on-Chronic Liver Failure (ACLF) franchise programs, notably NTZ/G1090N, SRT-015, CLM-022 and VS-02 HE, as well as our GNS561 program in cholangiocarcinoma (CCA). Cash consumption was partially offset by two significant cash inflows during the first half of 2026: (i) the second €30.0 million tranche received under the royalty financing agreement and (ii) the receipt of the first commercial milestone from Ipsen totaling €17.0 million ($20.0 million), which had been recognized in 2025 and was received in cash in 2026. Cash runway We expect that our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements beyond the end of 2028, enabling the Company to further develop its R&D pipeline and support general corporate purposes. Beyond this period, as sales of elafibranor increase, we expect related cash flows to become an increasingly important source of funding, with the objective of ultimately financing our operations and future development through cash generated by the business. This is based on current assumptions and programs and does not include exceptional events. In particular, this assumes (i) the continued commercial performance of Iqirvo® (elafibranor) and resulting royalties, (ii) the expectation to receive significant commercial milestones under the Ipsen Agreement, (iii) maintaining operating expenses at levels broadly consistent with current expectations, (iv) the development of revenues from our diagnostic activities, and (v) the possibility to draw down, if needed, the third and final installment of the Royalty Financing agreement. Revenue Revenue Nine-months ended (In € thousands) 30/09/2025 30/09/2026 Royalty revenue 12,596 36,308 Milestone revenue 26,556 0 Other revenue 81 125 Total 39,233 36,433 Royalty revenue Virtually all royalty revenue is derived from worldwide sales of Ipsen's Iqirvo 2 (elafibranor) under the Ipsen Agreement. These are utilized to repay the Group's Royalty Financing agreement. Year-over-year growth for the periods presented was 188%, reflecting accelerating U.S. sales and strong performance across Europe and other markets. Milestone revenue On May 20, 2025, GENFIT announced that Ipsen’s Iqirvo (elafibranor) was granted pricing and reimbursement in Italy for Primary Biliary Cholangitis (PBC), the third major European country to do so in addition to the UK and Germany. This third approval triggered a milestone payment of €26.5 million under GENFIT's Licensing and Collaboration Agreement with Ipsen, due upon pricing and reimbursement of Iqirvo (elafibranor) in three major European markets. Year-over-year revenue comparisons should consider the timing of milestone payments. Revenue for the nine months ended September 30, 2025 included a milestone payment, while no milestone revenue was recognized in the nine months ended September 30, 2026. Additional milestone revenue may however be recognized in future periods. Corporate update Elafibranor in cholestatic liver diseases Primary Biliary Cholangitis (PBC) - Iqirvo net sales reached €109.4 million in Q3 2026, compared with €48.6 million in Q3 2025, representing 125.4% year-over-year growth at constant exchange rates (CER). For the first nine months of 2026, net sales reached €282.6 million, versus €107.4 million over the same period in 2025, representing 170.8% growth at CER. 3 Iqirvo is leading growth within Rare Disease, Ipsen’s fastest-growing franchise. Earlier in July, Ipsen upgraded its peak sales estimates from €500 million to €1 billion in PBC. This revision followed Ipsen's announcement on July 13, 2026 4 , that the primary endpoint of alkaline phosphatase (ALP) normalization had been achieved in 85% of patients treated with Iqirvo (elafibranor), compared with 23% of patients receiving placebo at Week 52, in the Phase 3 ELSPIRE study. Next steps: Following positive results of the ELSPIRE study, regulatory submission is underway for PBC label update. Ipsen intends to publish its full-year results and fourth-quarter sales on February 11, 2027. Primary Sclerosing Cholangitis (PSC) - Phase 3 ELASCOPE study launched early 2026 is still ongoing. The market opportunity in PSC is estimated to be comparable in size to the second‑line PBC market. Subject to successful development and regulatory approval of elafibranor in this indication, GENFIT would be eligible to receive additional milestone payments as well as incremental double‑digit royalties. Next steps : Data readout expected around 2031. Non-invasive diagnostic technology in Metabolic dysfunction‑Associated SteatoHepatitis (MASH) Medicare reimbursement for Labcorp's NASHnext® 2 test (based on GENFIT's NIS™ technology) became effective in August 2026 (under the Clinical Laboratory Fee Schedule) for patients meeting coverage criteria. GENFIT believes broader reimbursement by private payers, if obtained, could support accelerated adoption of its technology over time. Further market expansion could also be supported by a potential future In Vitro Diagnostics (IVD) launch, which may facilitate deployment across a wider range of healthcare settings. In September, based on intention-to-diagnose data collected across key specialties, increasing disease prevalence, and a staged commercialization strategy spanning Laboratory Developed Tests (LDT) and IVD, IQVIA estimated that U.S. peak annual sales of products using GENFIT's technology could exceed $1.5 billion by 2033, with annual testing volume in the U.S. reaching more than 7 million tests. 5 GENFIT is engaging with stakeholders at AASLD The Liver Meeting® 2026 (November 5-9) to raise awareness of the evolving evidence supporting non-invasive approaches to identifying patients with at-risk MASH, including its NIS™ Technology. Next steps : GENFIT intends to outline its industrial strategy for the development and large-scale commercialization of an IVD kit based on its NIS™ Technology toward year-end. Subject to successful development, regulatory approval, partner execution and market adoption, GENFIT believes a potential commercial launch from 2028 could contribute to a meaningful acceleration in NIS™-related revenues over time. R&D pipeline Nangibotide to be evaluated in Phase 2 in ACLF - In summer 2026, GENFIT acquired the nangibotide program, a differentiated late-stage asset targeting the TREM-1 pathway. Phase 2 development is supported by efficacy signals observed across three prior Phase 2 clinical trials in septic shock and Covid19, including statistically significant improvements in mortality and SOFA score in selected analyses, together with a favorable safety and tolerability pro more than 400 exposed subjects. Next steps: Nangibotide is expected to enter a Phase 2 study in ACLF by year-end, with data readout targeted in the second half of 2027. Nitazoxanide to be evaluated in Phase 2 in ACLF – Positive Phase 1 data reported in early 2026 confirmed the favorable safety pro NTZ and demonstrated multi‑modal biological activity, supporting its continued clinical development across the ACLF disease continuum. In March 2026, FDA granted Orphan Drug Designation for NTZ for the treatment of ACLF. Next steps: The proof‑of‑concept study initiated in the third quarter of 2026 is expected to deliver data in mid-2027. GNS561 to be evaluated in Phase 2 in combination, in KRAS mutated CCA – Encouraging preliminary data from the ongoing Phase 1b study evaluating GNS561 in combination with a MEK inhibitor in KRAS-mutated CCA were disclosed in December 2025 and June 2026, leading to the expansion of the study into additional cohorts. Next steps: Additional Phase 1b data expected by year-end; Phase 2 initiation on track by year-end, with data readout targeted for the second half of 2027. Research programs in ACLF and CCA – GENFIT is directing its capital and development resources towards the programs with the strongest translational rationale and clinical potential. Next steps: Further details will be provided as and when these programs advance into clinical development. END ABOUT GENFIT GENFIT is a biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases whose medical needs remain largely unmet. GENFIT is a pioneer in liver disease research and development with a rich history and a solid scientific heritage spanning more than two decades. Today, GENFIT focuses on Acute on-Chronic Liver Failure (ACLF) and associated conditions such as acute decompensation (AD) and hepatic encephalopathy (HE). It develops therapeutic assets which have complementary mechanisms of action, selected to address key pathophysiological pathways. GENFIT also targets other serious diseases, such as cholangiocarcinoma (CCA), urea cycle disorders (UCD) and organic acidemia (OA). Its R&D portfolio, covering several stages of development, ensures a constant news flow. GENFIT's expertise in developing high-potential molecules – from early to advanced pre-commercialization stages – culminated in 2024 with the accelerated approval of Iqirvo® (elafibranor) by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom for second-line treatment of Primary Biliary Cholangitis (PBC). Iqirvo® is now marketed in several countries. 6 Beyond therapies, GENFIT also has a diagnostic franchise including NIS2+® for the detection of Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH for non-alcoholic steatohepatitis). GENFIT, a BCorp™ certified company since 2025, is headquartered in Lille, France and has offices in Paris (France) and Cambridge, MA (USA). The Company is listed on the Euronext regulated market in Paris, Compartment B (Euronext: GNFT) and joined the CAC Mid 60 and SBF 120 indices on September 18, 2026. In 2021, Ipsen became one of GENFIT's largest shareholders, acquiring an 8% stake in the Company's capital. GENFIT FORWARD LOOKING STATEMENTS This press release contains certain forward-looking statements with respect to GENFIT, including, but not limited to, statements regarding the Company’s cash runway, revenue growth, spending and path to profitability; potential royalties, milestone payments and additional royalty financing; the development, regulatory prospects and commercial potential of elafibranor; the development, reimbursement, adoption and commercialization of products based on NIS™ Technology, related market projections and GENFIT’s revenue potential; and the advancement of its R&D programs, including anticipated clinical trial initiation and data readout timelines. The use of certain words, such as "believe", "potential", "expect", “target”, “may”, “will”, "should", "could", "if" and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on the current expectations and reasonable assumptions of the Company’s management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among others, the uncertainties inherent in the Company’s ability to advance its therapeutic programs and initiate and complete clinical trials; uncertainties relating to regulatory requirements and decisions, patient enrollment, clinical trial execution, safety findings, manufacturing and clinical supply; the possibility that findings from prior studies in other indications, preclinical research or ex vivo assays may not predict safety, efficacy or clinical benefit in patients with ACLF; uncertainties relating to the clinical utility, further validation, adoption and use of non-invasive MASH diagnostics, including for disease or treatment- response monitoring; changes in clinical practice, treatment uptake, reimbursement, access and applicable regulatory requirements; and the Company’s dependence on partners and other third parties whose plans and activities may change. Those risks and uncertainties also include those discussed or identified in the Company’s public filings with the AMF, including those listed in Chapter 2 "Risk Factors and Internal Control" of the Company's 2025 Universal Registration Document filed on April 3, 2026 (no. 26-0221) with the Autorité des marchés financiers ("AMF"), which is available on GENFIT's website ( ) and the AMF's website ( ), and those discussed in reports filed with the AMF or otherwise made public, by the Company, including the Half-Year 2026 Business and Financial Report. In addition, even if the results, performance, financial position and liquidity of the Company and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this press release. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise. Links to third-party websites and materials, in particular those of Ipsen, are provided for convenience only. GENFIT is not responsible for the content of such materials and does not endorse or adopt any forward-looking statements contained therein. CONTACTS GENFIT | Investors Jean-Christophe Marcoux - Chief Corporate Affairs Officer | Tel : + 33 3 20 16 40 00 | jean-christophe.marcoux@genfit.com Kevin Gardner – Life Science Advisors | kgardner@lifesciadvisors.com GENFIT | Media Bruno Arabian – Agence Maarc | Tel : 06 87 88 47 26 | bruno.arabian@maarc.fr Stephanie Boyer – Press relations | Tel : + 33 3 20 16 40 00 | stephanie.boyer@genfit.com GENFIT | 885 Avenue Eugène Avinée, 59120 Loos - FRANCE | +333 2016 4000 | 1 Unaudited financial information under IFRS 2 Iqirvo® and NASHnext® are registered trademarks of GENFIT SA 3 Ipsen press release - 22 October 2026 4 Ipsen press release - 13 July 2026 5 Regulatory authorization through the applicable local approval process is required for IVD products and has not yet been obtained. 6 Elafibranor is marketed and commercialized, notably in the U.S and Europe, by Ipsen under the trademark Iqirvo® Attachment GENFIT Reports Third Quarter 2026 Financial Information and Provides Corporate Update

ACLF – Advancing a multi-target therapeutic strategy GENFIT to host a scientific event on November 8, 2026 to outline its ACLF strategy and unveil a comprehensive clinical data package supporting the advancement of nangibotide into Phase 2 in this indicationThree poster presentations will provide new insights into the role of inflammation and immune dysregulation in acute liver failure, as well as further clinically relevant evidence of nitazoxanide’s anti-inflammatory activity, supporting its development in ACLFManagement to present at dedicated scientific meeting with NACSELD, a leading North American research consortium in cirrhosis and ACLF, to deepen scientific engagement MASH Diagnostics – Unlocking the opportunity as MASH treatment uptake expands Taking a leading role in the Global Liver Institute’s Beyond the Biopsy – National Implementation Forum, bringing together drug manufacturers such as Novo Nordisk, Eli Lilly and Madrigal as well as KOLs to drive ecosystem-wide action on earlier patient identification and improved awareness of when, why and how to diagnose and monitor MASHGENFIT’s expert panel on November 6, 2026, will highlight the importance of non-invasive testing in MASH for early detection of patients with active fibrotic MASH and monitoring of treatment response, as well as the unique potential of NIS™ Technology through converging perspectives from hepatology, diabetology, endocrinology, the pharmaceutical industry, and patients Lille (France), Cambridge (Massachusetts, United States), November 2, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced a broad program of scientific and strategic activities taking place at the AASLD The Liver Meeting® 2026, highlighting progress across its therapeutic programs in Acute on-Chronic Liver Failure (ACLF) and diagnostics activities in Metabolic dysfunction-associated steatohepatitis (MASH). ACLF – Advancing a multi-target therapeutic strategy Scientific Event – November 8, 2026 |Advancing Clinical Development in ACLFBuilding on Extensive Clinical Evidence and ResearchThe event will feature Professor Jennifer Lai (UC San Francisco) as a guest speaker, and will outline GENFIT’s multi-target approach to ACLF, aimed at addressing the complex pathophysiology of the disease through complementary therapeutic mechanisms. It will also provide an in-depth review of nangibotide, GENFIT’s TREM-1 modulator combining a strong biological rationale including safety data and promising efficacy signals across multiple organ systems from previous clinical studies in different indications. The development package for nangibotide includes an existing body of clinical evidence at the proposed dose, as well as available clinical supply and regulatory data informing GENFIT’s decision to advance into Phase 2 in ACLF. Scientific posters to be presented – November 6, 2026 | 1:00–2:00 p.m. MT Poster #2284: RIPK1 inhibition attenuates NET release and hemorrhagic liver injury in D-Galactosamine/LPS micePoster #2273: D-Galactosamine/LPS Acute Liver Failure Recapitulates Emergency Granulopoiesis-like Signatures Across the Bone Marrow–Spleen–Liver AxisPoster #2034: Ex vivo blood assays demonstrate systemic anti-inflammatory activity of G1090N, a novel formulation of nitazoxanide, and support further clinical evaluation in acute-on-chronic liver failure (ACLF) ACLF is characterized by high systemic inflammation and profound immune dysregulation. By bridging systemic immune dysregulation and pharmacological intervention, posters #2284 and #2273 presented at The Liver Meeting® will provide new insights into the role of the immune system, particularly neutrophils, in acute liver failure conditions. In addition, poster #2034 will provide further evidence of nitazoxanide’s anti-inflammatory activity, using blood samples collected in a clinical setting, supporting its clinical development in ACLF. NACSELD Meeting – November 5, 2026 The North American Consortium for the Study of End-Stage Liver Disease (NACSELD), a leading multicenter research consortium focused on improving outcomes in cirrhosis and ACLF, will host a dedicated scientific meeting to provide an opportunity to discuss the evolving understanding of ACLF, key unmet needs and priorities for future therapeutic development, deepening scientific engagement. Building on GENFIT’s established partnership with NACSELD, management will present its ACLF strategy at this meeting chaired by Professor Jasmohan S. Bajaj, MD, MS, FAASLD, of Virginia Commonwealth University. MASH Diagnostics – Unlocking the opportunity as MASH treatment uptake expands “Beyond the Biopsy” National Implementation Forum – November 4, 2026 | Global Liver Institute’s Initiative The Global Liver Institute’s “Beyond the Biopsy “ National Implementation Forum will bring together clinical experts, patients, and diagnostics and pharmaceutical companies to address the practical barriers to implementing non-invasive MASH diagnostics at scale. Building on patient experiences and insights about LITMUS and NIMBLE, discussions moderated by Professor Brent A. Tetri, MD, will examine how to translate diagnostic innovation into real-world implementation across clinical pathways, access, reimbursement and policy. This involvement further strengthens GENFIT’s ties with Eli Lilly, Novo Nordisk, Madrigal and other leading pharmaceutical companies at the forefront of bringing new treatment options to tens of millions of patients in need. Larry Holden, CEO of the Global Liver Institute commented: “We are reaching an important inflection point in MASH: effective treatments are becoming available, making the ability to identify the right patients, particularly those with at-risk MASH, increasingly critical. Bringing together diagnostic innovators such as GENFIT, leading drug companies including Eli Lilly, Novo Nordisk and Madrigal, clinical experts from hepatology to endocrinology, patients and payers around the same table is exactly the type of dialogue needed to move from scientific progress to real-world implementation. As a pioneer in non-invasive MASH diagnostics, GENFIT has helped shape the field and continues to drive its evolution, with a clear vision of a future where therapeutic advances go hand in hand with effective patient identification and disease monitoring.” Expert Panel – November 6, 2026 | Non-Invasive Diagnostics for At-Risk MASH NISTM Technology Reshaping Patient Identification and Access to Care1Professor Vlad Ratziu, MD, PhD (Sorbonne University, Pitié-Salpêtrière Hospital, IHU ICAN) and Professor Kenneth Cusi, MD, FACP, FACE (University of Florida, Division of Endocrinology, Diabetes & Metabolism) will share complementary hepatology and metabolic disease perspectives, while Wayne Eskridge and Henry Chang from the Fatty Liver Foundation will highlight how a simple and reliable blood-based technology could transform the patient journey and improve patient outcomes. Ashley Hamilton Chasick (Global Lead, Diagnostics Partnerships, Novo Nordisk), will complement these perspectives with an industry view on the importance of adopting non-invasive diagnostics in clinical practice to support earlier identification and monitoring of patients with at-risk MASH. The discussion will address current challenges in identifying and managing patients with at-risk MASH, a population characterized not only by fibrosis, but also by disease activity. It will highlight the growing role of non-invasive diagnostics as treatment uptake expands, and the potential contribution of GENFIT’s NIS™ Technology. Independent consortia in the US and Europe have validated GENFIT’s technology: NIMBLE identified it as the only one, among those evaluated, specifically intended to diagnose at-risk MASH, while LITMUS showed that it achieved the highest diagnostic accuracy among the blood-based, imaging and combined modalities evaluated for at-risk MASH. At-risk MASH is consistent with the population enrolled in the pivotal Phase 3 trials that supported the approval of currently approved MASH therapies. GENFIT’s partner Ipsen is also expected to communicate on elafibranor during The Liver Meeting® 2026. END ABOUT GENFIT GENFIT is a biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases whose medical needs remain largely unmet. GENFIT is a pioneer in liver disease research and development with a rich history and a solid scientific heritage spanning more than two decades. Today, GENFIT focuses on Acute on-Chronic Liver Failure (ACLF) and associated conditions such as acute decompensation (AD) and hepatic encephalopathy (HE). It develops therapeutic assets which have complementary mechanisms of action, selected to address key pathophysiological pathways. GENFIT also targets other serious diseases, such as cholangiocarcinoma (CCA), urea cycle disorders (UCD) and organic acidemia (OA). Its R&D portfolio, covering several stages of development, ensures a constant news flow. GENFIT's expertise in developing high-potential molecules – from early to advanced pre-commercialization stages – culminated in 2024 with the accelerated approval of Iqirvo® (elafibranor) by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom for second-line treatment of Primary Biliary Cholangitis (PBC). Iqirvo® is now marketed in several countries.2 Beyond therapies, GENFIT also has a diagnostic franchise including NIS2+® for the detection of Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH for non-alcoholic steatohepatitis). GENFIT, a BCorp™ certified company since 2025, is headquartered in Lille, France and has offices in Paris (France) and Cambridge, MA (USA). The Company is listed on the Euronext regulated market in Paris, Compartment B (Euronext: GNFT). In 2021, Ipsen became one of GENFIT's largest shareholders, acquiring an 8% stake in the Company's capital. www.genfit.com FORWARD LOOKING STATEMENTS This press release contains certain forward-looking statements with respect to GENFIT, including, but not limited to, statements regarding the development and potential therapeutic profile of nangibotide, the potential role of TREM-1 in Acute-on-Chronic Liver Failure (ACLF), the initiation, design, conduct, timing and results of future clinical trials, including the planned Phase 2a proof-of-concept study in ACLF, the potential clinical benefits, safety profile and therapeutic value of nangibotide, the potential relevance on future clinical investigations of efficacy signals and safety data observed in prior clinical studies conducted in other indications, the expected timing of data readouts, regulatory interactions and future development activities, the potential role, clinical utility and adoption of non-invasive MASH diagnostics, including GENFIT’s NIS™ Technology, in patient identification, disease monitoring and access to care; the potential opportunities associated with increasing uptake of MASH treatments, as well as the Company's strategic plans and objectives. The use of certain words, such as "believe", "potential", "expect", “target”, “may”, “will”, "should", "could", "if" and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on the current expectations and reasonable assumptions of the Company’s management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among others, the uncertainties relating to the the Company’s ability to advance its therapeutic programs and initiate and complete clinical trials; uncertainties relating to regulatory requirements and decisions, patient enrollment, clinical trial execution, safety findings, manufacturing and clinical supply; the possibility that findings from prior studies in other indications, preclinical research or ex vivo assays may not predict safety, efficacy or clinical benefit in patients with ACLF; uncertainties relating to the clinical utility, further validation, adoption and use of non-invasive MASH diagnostics, including for disease or treatment- response monitoring; changes in clinical practice, treatment uptake, reimbursement, access and applicable regulatory requirements; and the Company’s dependence on partners and other third parties whose plans and activities may change. Those risks and uncertainties also include those discussed or identified in the Company’s public filings with the AMF, including those listed in Chapter 2 "Risk Factors and Internal Control" of the Company's 2025 Universal Registration Document filed on April 3, 2026 (no. 26-0221) with the Autorité des marchés financiers ("AMF"), which is available on GENFIT's website (www.genfit.fr) and the AMF's website (www.amf.org), and those discussed in reports filed with the AMF or otherwise made public, by the Company including the Half-Year 2026 Business and Financial Report. In addition, even if the results, performance, financial position and liquidity of the Company and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this press release. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise. CONTACTS GENFIT | Investors Jean-Christophe Marcoux – Chief Corporate Affairs Officer | Tel: +33 3 2016 4000 | jean-christophe.marcoux@genfit.com Kevin Gardner – Life Science Advisors | kgardner@lifesciadvisors.com GENFIT | Media Bruno ARABIAN – Agence Maarc | Tel : 06 87 88 47 26 | bruno.arabian@maarc.fr Stephanie Boyer – Press relations | Tel: +333 2016 4000 | stephanie.boyer@genfit.com GENFIT | 885 Avenue Eugène Avinée, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com 1 NIS™ Technology refers to NIS4® and its next-generation version, NIS2+® | NASHnext® (based on NIS4 technology) reimbursement by Medicare under the Clinical Laboratory Fee Schedule to Medicare patients that meet coverage criteria became effective on August 10, 2026 | NIS2+® is currently available through Labcorp in the United States as a Laboratory Developed Test (LDT). It has not been cleared or approved by the U.S. Food,and Drug Administration (FDA) and is not CE marked in the European Union2 Elafibranor is marketed and commercialized, notably in the U.S and Europe, by Ipsen under the trademark Iqirvo® Attachment GENFIT to Highlight Progress in ACLF and MASH Diagnostics at AASLD The Liver Meeting® 2026